Clinical Trial

A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001

Study acronym: DINGO
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase 1/2 repeat-dose, open-label, two-arm, parallel group safety and efficacy study of two doses of VP-001 (30 μg and 75 μg) in participants with confirmed PRPF31 mutation-associated retinal dystrophy, including participants previously treated with VP001 in the PLATYPUS Study or WALLABY Study for a minimum of 8 weeks.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-02-24; most recent amendment 2026-05-27.
Status change: Recruiting → Active, Not Recruiting 2026-05-27
Status change: Not Yet Recruiting → Recruiting 2025-11-24
Trial Details
NCT Number NCT06852963
Lead Sponsor PYC Therapeutics
Conditions Retinitis Pigmentosa 11, Retinal Degeneration, Retinal Disease, Eye Diseases Hereditary, Retinal Dystrophies
Enrollment 17 participants
Start Date 2025-06-01
Primary Completion 2028-03-08 (estimated)
Study Completion 2028-04-21 (estimated)
Updated on ClinicalTrials.gov 2026-05-29